Introduction
============

As a generic term for intracranial vascular disease associated with various neurological and pathological processes, cerebral small vessel disease (CSVD) refers to a syndrome of different clinical features and neuroimaging findings induced by pathological changes in capillaries, perforating cerebral arterioles and venules ([@ref-38]). CSVD is the cause of 45% of all the cases of dementia, and accounts for 25% of the ischemic stroke cases around the world ([@ref-26]; [@ref-29]; [@ref-42]). Additionally, CSVD is a major cause for depression, cognitive impairment, disability and so on in the aged ([@ref-21]).

The pathogenesis for CSVD mainly includes impairment of cerebral autoregulation, reduction of cerebral blood flow and increase of blood--brain barrier (BBB) permeability ([@ref-17]; [@ref-21]; [@ref-22]). However, its molecular mechanisms are not completely elucidated. Genetic studies have demonstrated that CSVD is highly heritable, especially in young-onset stroke patients, and that disease processes of some CSVD subtypes may be associated with common variants in monogenic disease genes ([@ref-39]).

Methylenetetrahydrofolate reductase (MTHFR) gene is located on chromosome 1p36.3, and it is associated with the biosynthesis pathway of amino acid and purine ([@ref-9]; [@ref-6]). As an important regulatory enzyme catalyzing the transformation of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, MTHFR is indispensable for the conversion of homocysteine (Hcy) to methionine ([@ref-33]; [@ref-31]). The single nucleotide polymorphism (SNP) of MTHFR gene ([rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133), C667T) is correlated with decreased enzyme activity that eventually results in elevated plasma homocysteine levels ([@ref-7]; [@ref-18]). Hyperhomocysteinemia has been confirmed to be involved in the pathogenesis of stroke, CSVD, various metabolic disorders and so on ([@ref-13]; [@ref-44]; [@ref-5]; [@ref-34]; [@ref-24]; [@ref-30]; [@ref-19]; [@ref-15]; [@ref-27]). In addition, a recent study suggested that MTHFR C677T genotype was associated with CSVD subtype ([@ref-36]). However, no previous studies have investigated the mechanism associated with the effect of MTHFR C677T genotype on CSVD susceptibility. In this study, the relationship between SNPs of MTHFR gene ([rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133), [rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131), [rs2274976](http://www.ncbi.nlm.nih.gov/snp/?term=rs2274976), [rs4846048](http://www.ncbi.nlm.nih.gov/snp/?term=rs4846048), [rs4846049](http://www.ncbi.nlm.nih.gov/snp/?term=rs4846049), [rs13306561](http://www.ncbi.nlm.nih.gov/snp/?term=rs13306561) and [rs3737964](http://www.ncbi.nlm.nih.gov/snp/?term=rs3737964)) and CSVD was determined after adjusting for cardiovascular risk factors, and the potential mechanism based on Hcy levels was explored. The aim was to provide useful clues for identifying susceptible populations of CSVD.

Materials & Methods
===================

Participants
------------

A total of 163 consecutive patients with CSVD were collected as the case group in Heze Municipal Hospital between April 2017 and October 2018. In the corresponding period, 326 healthy people were selected as the control group, who were matched to these cases according to age (±2 years) and gender at a ratio of 2:1. This study received the permission of the ethic committee of Heze Municipal Hospital (20160141022), and written informed consent was provided by each participant.

The inclusion criteria of CSVD patients were (1) in accordance with the diagnostic criteria suggested by [@ref-38]; (2) to demonstrate typical neuroimaging changes in the subcortical grey matter and white matter, including white matter hyperintensities (WMHs), prominent perivascular spaces (PVS), cerebral microbleeds (CMBs), atrophy, lacunas and recent small subcortical infarct ([@ref-42]); (3) complete clinical data; (4) written informed consent. The exclusion criteria included (1) large-artery atherosclerosis; (2) a definite history of subarachnoid hemorrhage or cerebral hemorrhage; (3) acute ischemic stroke caused by cardiogenic embolism.

Data collection
---------------

Demographic data, cardiovascular risk factors and laboratory indexes were collected in each participant. Demographic data included age, gender, height, weight, annual family income, education level and occupation. Cardiovascular risk factors included hypertension, hyperlipemia, diabetes, smoking, drinking and blood pressure. Laboratory indexes included total cholesterol, triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and fasting blood glucose (FBG).

SNP genotyping for MTHFR gene
-----------------------------

The DNA used in SNP genotyping was extracted from peripheral blood using the salting out method suggested by [@ref-11]. TaqMan Pre-Designed SNP Genotyping Assays (Applied Biosystems, Carlsbad, USA) was employed to perform SNP genotyping for the MTHFR gene ([rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133), [rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131), [rs2274976](http://www.ncbi.nlm.nih.gov/snp/?term=rs2274976), [rs4846048](http://www.ncbi.nlm.nih.gov/snp/?term=rs4846048), [rs3737966](http://www.ncbi.nlm.nih.gov/snp/?term=rs3737966), [rs1537515](http://www.ncbi.nlm.nih.gov/snp/?term=rs1537515), [rs4846049](http://www.ncbi.nlm.nih.gov/snp/?term=rs4846049), [rs3834044](http://www.ncbi.nlm.nih.gov/snp/?term=rs3834044), [rs13306561](http://www.ncbi.nlm.nih.gov/snp/?term=rs13306561) and [rs3737964](http://www.ncbi.nlm.nih.gov/snp/?term=rs3737964)). The ABI 7500 Fast real-time PCR system (Applied Biosystems, Carlsbad, USA) was employed to perform PCR amplification and allelic discrimination.

Plasma Hcy assay
----------------

The blood sample was collected from the antecubital vein after an overnight fasting in each participant. The blood sample was then separated through centrifugation at 3,000 g for 5 min. The level of Hcy was detected by enzymatic cycling assay using Hcy reagent (Beijing Strong Biotechnologies, Inc, Beijing, China) and the ROCHE Cobas 8000 automatic biochemical analyzer (Roche Ltd., Switzerland).

Statistical analysis
--------------------

Haploview software version 4.2 (<http://www.broad.mit.edu/mpg/haploview>; developed in Mark Daly's laboratory at the Broad Institute) was employed to perform Hardy-Weinberg equilibrium (HWE) test and to calculate allele frequencies and genotype frequencies for all the SNPs ([@ref-2]). Univariate analysis was performed with Student's *t-* test or chi-square test for all variables, including demographic data, vascular risk factors, laboratory indexes and SNP genotyping data. The variables with a *P* value less than 0.10 were then included in the multivariate analysis, which was used to identify the SNPs associated with CSVD susceptibility through a backward stepwise logistic regression model. Plasma Hcy levels among different genotypes were compared using ANOVA. All statistical analysis was conducted using the SPSS version 20.0 for Windows (SPSS Inc., USA), and significance was set at *P* \< 0.05.

Results
=======

Univariate analysis of demographic data, vascular risk factors and laboratory indexes
-------------------------------------------------------------------------------------

The case group included 94 males and 69 females, and the control group included 188 males and 138 females. Their average age was (63.28 ± 7.09) years. Univariate analysis demonstrated that age, body mass index (BMI), annual family income, education level, occupation, drinking, hyperlipidaemia, total cholesterol, TG, LDL-C and HDL-C were not statistically different between the case group and the control group, and hypertension, diabetes, smoking, systolic blood pressure (SBP), diastolic blood pressure (DBP) and FBG were statistically different ([Table 1](#table-1){ref-type="table"}).
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###### Univariate analysis results of demographic data, vascular risk factors and laboratory indexes.

![](peerj-08-8627-g001)

                                                            Case group (*n* = 163)   Control group (*n* = 326)   *χ2*/*t*   *P*
  ------------------------------ -------------------------- ------------------------ --------------------------- ---------- ---------
  Age (Years)                                               63.42 ± 7.13             63.21 ± 6.98                0.309      0.804
  BMI (Kg/m^2^)                                             22.18 ± 4.61             22.37 ± 4.95                0.419      0.716
  Annual family income (RMB)     \<10,000                   18(11.04%)               39(11.96%)                  0.138      0.933
  10,000--20,000                 48(29.45%)                 92(28.22%)                                                      
  \>20,000                       97(59.51%)                 195(59.82%)                                                     
  Educational level              Primary school and below   69(42.33%)               130(39.88%)                 0.596      0.742
  Junior high school             58(35.58%)                 114(34.97%)                                                     
  Senior high school and above   36(22.09%)                 82(25.15%)                                                      
  Occupation                     Farmer                     71(43.56%)               131(40.18%)                 0.788      0.674
  Worker                         61(37.42%)                 123(37.73%)                                                     
  Civil servant/teacher/doctor   31(19.02%)                 72(22.09%)                                                      
  Drinking                       Yes                        40(24.54%)               74(22.70%)                  0.206      0.650
  No                             123(75.46%)                252(77.30%)                                                     
  Hyperlipidaemia                Yes                        48(29.45%)               73(22.39%)                  2.905      0.088
  No                             115(70.55%)                253(77.61%)                                                     
  Total cholesterol (mmol/L)                                4.45 ± 1.53              4.30 ± 1.41                 1.049      0.319
  TG (mmol/L)                                               1.54 ± 1.22              1.42 ± 1.09                 1.062      0.311
  LDL-C (mmol/L)                                            2.62 ± 1.34              2.39 ± 1.37                 1.776      0.073
  HDL-C (mmol/L)                                            1.24 ± 0.48              1.33 ± 0.56                 1.847      0.068
  Hypertension                   Yes                        54(33.13%)               66(20.25%)                  9.740      0.002
  No                             109(66.87%)                260(79.75%)                                                     
  Diabetes                       Yes                        50(30.67%)               64(19.63%)                  6.797      0.009
  No                             116(69.33%)                262(80.37%)                                                     
  Smoking                        Yes                        49(30.06%)               65(19.94%)                  6.228      0.013
  No                             114(69.94%)                261(80.06%)                                                     
  SBP (mmHg)                                                144.83 ± 13.92           138.78 ± 13.88              4.535      \<0.001
  DBP (mmHg)                                                90.74 ± 9.08             86.96 ± 8.64                4.41       \<0.001
  FBG (mmol/L)                                              6.62 ± 2.85              5.59 ± 2.17                 4.063      \<0.001

**Notes.**

BMIBody mass indexTGTriacylglycerolLDL-CLow density lipoprotein cholesterolHDL-CHigh density lipoprotein cholesterolSBPSystolic blood pressureDBPDiastolic blood pressureFBGFasting blood glucose

SNP analysis
------------

All the SNPs were successfully genotyped in both the case group and the control group. As shown in [Table 2](#table-2){ref-type="table"}, the genotype frequencies of all the SNPs were not statistically different from those evaluated using Hardy-Weinberg equilibrium. Univariate analysis demonstrated that the genotype frequencies of [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) (*χ*^2^ = 12.852, *P* = 0.002) and [rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131) (*χ*^2^ = 6.203, *P* = 0.045) were statistically different between the case group and the control group, and [rs2274976](http://www.ncbi.nlm.nih.gov/snp/?term=rs2274976), [rs4846048](http://www.ncbi.nlm.nih.gov/snp/?term=rs4846048), [rs4846049](http://www.ncbi.nlm.nih.gov/snp/?term=rs4846049), [rs13306561](http://www.ncbi.nlm.nih.gov/snp/?term=rs13306561) and [rs3737964](http://www.ncbi.nlm.nih.gov/snp/?term=rs3737964) were not statistically different (all *P* \> 0.05).
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###### Univariate analysis results of allele and genotype frequency.

![](peerj-08-8627-g002)

                                                                                   Allele frequency n(%)   Genotype frequency n(%)   HWE *P*                                
  ---------------------------------------------------------------- --------------- ----------------------- ------------------------- ------------ ------------ ------------ --------
  [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133)                     C                       T                         CC           CT           TT           
                                                                   Case group\*    125(38.34)              201(61.66)                28(17.18)    69(42.33)    66(40.49)    \>0.05
                                                                   Control group   325(49.85)              327(50.15)                106(32.52)   113(34.66)   107(32.82)   \>0.05
  [rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131)                     A                       C                         AA           AC           CC           
                                                                   Case group\*    282(86.50)              44(13.50)                 126(77.30)   30(18.40)    7(4.30)      \>0.05
                                                                   Control group   516(79.14)              136(20.86)                219(67.18)   78(23.93)    29(8.90)     \>0.05
  [rs2274976](http://www.ncbi.nlm.nih.gov/snp/?term=rs2274976)                     A                       G                         AA           AG           GG           
                                                                   Case group      28(8.59)                298(91.41)                2(1.22)      24(14.72)    137(84.05)   \>0.05
                                                                   Control group   61(9.36)                591(90.64)                6(1.84)      49(15.03)    271(83.13)   \>0.05
  [rs4846048](http://www.ncbi.nlm.nih.gov/snp/?term=rs4846048)                     A                       G                         AA           AG           GG           
                                                                   Case group      288(88.34)              38(11.66)                 125(76.69)   38(23.31)    0(0)         \>0.05
                                                                   Control group   581(89.11)              71(10.89)                 255(78.22)   71(21.78)    0(0)         \>0.05
  [rs4846049](http://www.ncbi.nlm.nih.gov/snp/?term=rs4846049)                     G                       T                         GG           GT           TT           
                                                                   Case group      263(80.67)              63(19.33)                 106(65.03)   51(31.29)    6(3.68)      \>0.05
                                                                   Control group   525(80.52)              127(19.48)                213(65.34)   99(30.37)    14(4.29)     \>0.05
  [rs13306561](http://www.ncbi.nlm.nih.gov/snp/?term=rs13306561)                   C                       T                         CC           CT           TT           
                                                                   Case group      29(8.90)                297(91.10)                3(1.84)      23(14.11)    137(84.05)   \>0.05
                                                                   Control group   53(8.13)                599(91.87)                4(1.23)      45(13.80)    277(84.97)   \>0.05
  [rs3737964](http://www.ncbi.nlm.nih.gov/snp/?term=rs3737964)                     A                       G                         AA           AG           GG           
                                                                   Case group      37(11.35)               289(88.65)                0(0)         37(22.70)    126(77.30)   \>0.05
                                                                   Control group   73(11.20)               579(88.80)                0(0)         73(22.39)    253(77.61)   \>0.05

**Notes.**

*P* \< 0.05, *vs* allele frequency and genotype frequency of the control group.

HWE, Hardy--Weinberg equilibrium

Multivariate analysis
---------------------

Multivariate analysis was performed to identify the independent association between different genotypes of the MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) and [rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131) and CSVD. The results demonstrated that the polymorphism of [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) was correlated with CSVD after adjusting hypertension, diabetes, smoking, SBP, DBP, FBG, hyperlipidaemia, LDL-C and HDL-C, but [rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131) was not ([Table 3](#table-3){ref-type="table"}). The MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) TT and CT genotype had increased risk for CSVD, and the *OR* was higher in the TT genotype than in the CT genotype (2.307 vs 1.473).
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###### Independent association between different genotypes of the MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) and [rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131) and CSVD.

![](peerj-08-8627-g003)

                                                                 Regression coefficient   Standard error   Wald     *OR*    95% *CI*       *P*
  -------------------------------------------------------------- ------------------------ ---------------- -------- ------- -------------- ---------
  [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133)                                             9.759                           \<0.001
  CC                                                                                                                ---     ---            Ref=1
  CT                                                             0.307                    0.154            7.528    1.473   1.164--2.258   0.003
  TT                                                             0.416                    0.209            11.063   2.307   1.798--4.141   \<0.001
  [rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131)                                             1.065                           0.262
  AA                                                                                                                ---     ---            Ref=1
  AC                                                             0.163                    0.122            0.975    0.821   0.602--1.479   0.323
  CC                                                             0.218                    0.126            1.147    0.726   0.517--1.368   0.218

**Notes.**

MTHFRMethylenetetrahydrofolate reductaseCSVDCerebral small vessel disease*OR*odds ratio*CI*confidence interval

Plasma Hcy levels
-----------------

Plasma Hcy levels were compared using ANOVA between the MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) TT, CT and CC genotype. The results demonstrated that plasma Hcy levels were highest in the TT genotype, intermediate in the CT genotype, and lowest in the CC genotype ([Table 4](#table-4){ref-type="table"}).
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###### Plasma Hcy levels in the *MTHFR*[rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) CC, CT and TT genotype.

![](peerj-08-8627-g004)

                n     Plasma Hcy levels (pg/ml)
  ------------- ----- ---------------------------------------------------------------------------------------
  CC genotype   134   14.96 ± 4.85
  CT genotype   182   17.04 ± 5.68[^\*^](#table-4fn1){ref-type="fn"}
  TT genotype   173   19.91 ± 8.73[^\*^](#table-4fn1){ref-type="fn"}^,^[^\*\*^](#table-4fn2){ref-type="fn"}
  *F*                 9.094
  *P*                 \<0.001

**Notes.**

*P* \< 0.05, *vs* CC genotype.

*P* \< 0.05, *vs* CT genotype.

Joint effect of MTHFR 677C\>T ([rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133)) and 1298A\>C ([rs1801131](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801131)) on plasma Hcy levels
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The combination of genotypes 677TT and 1298CC was abbreviated TTCC, 677TT and 1298AA was abbreviated TTAA, etc. The frequencies of the nine combination genotypes derived from the both polymorphisms were TTAA (35.17%, 172/489), CTAA (24.34%, 119/489), CTAC (12.68%, 62/489), CCAC (11.25%, 55/489), CCAA (8.90%, 44/489), CCCC (7.16%, 35/489), CTCC (0.20%, 1/489), TTAC (0.20%, 1/489) and TTTC (0, 0%) in all participants.

The distribution of the six common combination genotypes was significantly different between the case group and the control group ([Table 5](#table-5){ref-type="table"}). Plasma Hcy levels were highest in TTAA genotype, and moderate in CTAA and CTAC genotypes, and lowest in CCAC, CCAA and CCCC genotypes. However, the difference was not significant between CTAA and CTAC genotypes and also between CCAC, CCAA and CCCC genotypes ([Table 6](#table-6){ref-type="table"}).
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###### Frequencies of the six common combination genotypes.

![](peerj-08-8627-g005)

                  Six common genotype combinations *n*(%)                                                   
  --------------- ----------------------------------------- ----------- ----------- ----------- ----------- ----------
  Case group      66(40.49)                                 47(28.83)   22(13.50)   6(3.68)     18(11.04)   4(2.45)
  Control group   106(32.52)                                72(22.09)   40(12.27)   49(15.03)   26(7.98)    31(9.51)
  *χ*^2^          25.211                                                                                    
  *P*             \<0.001                                                                                   
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###### Plasma Hcy levels of the six common combination genotypes.

![](peerj-08-8627-g006)

         *n*   Plasma Hcy levels (pg/ml)
  ------ ----- -----------------------------------------------------------------------------------------------------------------------------
  TTAA   172   19.93 ± 8.71
  CTAA   119   17.76 ± 5.72[^\*^](#table-6fn1){ref-type="fn"}
  CTAC   62    16.32 ± 5.28[^\*^](#table-6fn1){ref-type="fn"}
  CCAC   55    14.75 ± 4.64[^\*^](#table-6fn1){ref-type="fn"}^,^[^\*\*^](#table-6fn2){ref-type="fn"}
  CCAA   44    15.94 ± 4.93[^\*^](#table-6fn1){ref-type="fn"}^,^[^\*\*^](#table-6fn2){ref-type="fn"}
  CCCC   35    14.06 ± 4.49[^\*^](#table-6fn1){ref-type="fn"}^,^[^\*\*^](#table-6fn2){ref-type="fn"}[^\*\*\*^](#table-6fn3){ref-type="fn"}
  *F*          6.275
  *P*          0.019

**Notes.**

*P* \< 0.05 *vs* TTAA genotype.

*P* \< 0.05, *vs* CTAA genotype.

*P* \< 0.05, *vs* CTAC genotype.

Discussion
==========

As a sulfur-containing amino acid, Hcy is an important intermediate product for the metabolism of methionine. Hcy has an important role in vascular function ([@ref-20]). Elevated Hcy levels can predispose vascular smooth muscle cells and endothelial cells to injury, which leads to activation of coagulation factors, expression of plasminogen activator inhibitor, endothelial proliferation and so on ([@ref-10]). This further inhibits the expression of thrombomodulin and synthesis of tissue-type plasminogen activator and sulfated heparin, eventually leading to atherogenesis and thrombogenesis through secretion of inflammatory cytokines, platelet aggregation, endoplasmic reticulum stress, and oxidative stress.

Studies show that Hyperhomocysteinemia (HHcy) is associated with many diseases, including ischemic stroke (IS), CSVD and various metabolic disorders and so on. [@ref-27] showed that elevated total Hcy was correlated with clinical status and severity of white matter changes in symptomatic patients with subcortical small vessel disease. HHcy has also been a confirmed independent risk factor for IS ([@ref-43]; [@ref-4]). [@ref-43] demonstrated that high Hcy levels were associated with a greater incidence of acute cerebral infarction among patients with carotid artery plaques. [@ref-16] reported that high Hcy levels were associated with a poor functional outcome, severe neurological impairment and stroke recurrence in large artery atherosclerosis stroke subtype, which confirmed the atherogenic effect of Hcy. [@ref-23] demonstrated that high Hcy levels were correlated with strong plaque enhancement and acute ischemic stroke with adjustment for sex, age, serum creatinine levels and other atherosclerotic risk factors. Several previous cohort studies also showed that high Hcy levels were correlated with increased risk of IS, including the British Regional Heart Study, the Framingham Study and the Northern Manhattan cohort study ([@ref-28]; [@ref-3]; [@ref-37]). As a risk factor of atherosclerosis, high Hcy levels are associated with white matter lesions, lacunar infarcts and cognitive impairment. [@ref-19] found that a higher Hcy level was associated with presence of lacunar infarcts and a higher volume of white matter lesions among patients with symptomatic atherosclerotic disease. [@ref-30] evaluated the association between Hcy levels and CSVD with the method of meta-analysis. Their results demonstrated that Hcy levels were higher in CSVD patients than in healthy controls. [@ref-24] found that serum Hcy levels were associated with the presence of cerebral microbleeds, white matter hyperintensity volume enlarged perivascular spaces in a healthy population. In addition, Hcy levels may be correlated with the susceptibility for NAFLD ([@ref-12]; [@ref-32]).

MTHFR is a key controlling enzyme involved in the metabolism of Hcy and folate. It is indispensable for the conversion of homocysteine to methionine through catalyzing the transformation of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate ([@ref-33]; [@ref-31]). Additionally, it has a role in chromosomal integrity, DNA methylation and maintaining the stability of single- and double-strand DNA ([@ref-35]). It is encoded by the MTHFR gene, which is located on chromosome 1p36.3 ([@ref-9]). For the MTHFR gene, the cytosine (C) to thymine (T) substitution at position 677 ( [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133)) in the gene encoding region is the most common SNP. This variation leads to the conversion from alanine to valine at amino acid 222 ([@ref-14]), and is correlated with decrease of thermal stability of MTHFR and subsequent decrease of enzyme activity ([@ref-1]; [@ref-25]). Compared to the CC genotype, the enzyme activity of the CT and TT genotypes is less than 35% and 70%, respectively ([@ref-8]). The decreased enzyme activity eventually leads to the elevation of Hcy levels ([@ref-1]; [@ref-25]). In other words, the CT and TT genotypes are correlated with elevated Hcy levels through reducing the activity of MTHFR. [@ref-41] found that the SNP of the MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) and NAFLD had a potential synergistic effect on elevated Hcy levels. [@ref-20] found that the plasma Hcy levels of different genotypes of the MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) showed the tendency of the TT genotype \>CT genotype \>CC genotype. They concluded that a possible synergistic effect of the MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) SNP on plasma Hcy levels increased the risk of IS. In addition, Rutten-Jacobs et al. demonstrated that MTHFR C677T genotype was associated with CSVD subtype ([@ref-36]).

In this study, the SNP of the MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) was correlated with CSVD, and the TT and CT genotypes had increased risk for CSVD compared to the CC genotype. Moreover, the overall response (*OR)* was higher in the TT genotype than in the CT genotype. At the same time, the plasma Hcy levels of different genotypes showed the tendency of the TT genotype \>CT genotype \>CC genotype. Therefore, the SNP of [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) was correlated with CSVD through elevating Hcy levels. [@ref-40] demonstrated a strong linkage and functional inference of MTHFR 677C\>T and 1298A\>C polymorphisms through a large-scale epidemiological investigation. In this study, we further investigated the frequencies of combination genotypes of MTHFR 677C\>T and 1298A\>C in the case group and the control group. The results showed that the distribution of the six common combination genotypes was significantly different between the case group and the control group. Lastly, we investigated plasma Hcy levels of the six common combination genotypes. However, the results showed that the difference was not significant between CTAA and CTAC genotypes and also between CCAC, CCAA and CCCC genotypes. The reason might be associated with a small sample size.

In this study, the inclusion and exclusion criteria of CSVD patients used in this paper included clinical symptoms, signs and typical neuroimaging changes. Additionally, CSVD patients should have complete clinical data. A ratio of 2:1 was selected for control people: case people with the aim of improving the efficiency of the study through enhancing statistical power. The objective of this study was to evaluate the relationship between SNPs of MTHFR gene and CSVD comprehensively and precisely, and the main limitation was a small sample size. We will investigate the joint effect of MTHFR 677C\>T and 1298A\>C using a larger sample size in the next step.

Conclusions
===========

The SNP of the MTHFR [rs1801133](http://www.ncbi.nlm.nih.gov/snp/?term=rs1801133) was correlated with CSVD susceptibility through influencing Hcy levels.
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